

10 / 005,133

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Jun 03 New e-mail delivery for search results now available  
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 11 Oct 24 BEILSTEIN adds new search fields  
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 28 Mar 20 EVENTLINE will be removed from STN  
NEWS 29 Mar 24 PATDPAFULL now available on STN  
NEWS 30 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 31 Apr 11 Display formats in DGENE enhanced  
NEWS 32 Apr 14 MEDLINE Reload  
NEWS 33 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 34 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS  
NEWS 35 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX

NEWS EXPRESS APRIL 1 CURRENT WINDOW'S IS V6.0a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

10 / 005,133

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:09:55 ON 25 APR 2003

FILE 'REGISTRY' ENTERED AT 15:10:03 ON 25 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1  
DICTIONARY FILE UPDATES: 24 APR 2003 HIGHEST RN 505023-70-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
Uploading 10005133.str

L1 STRUCTURE UPLOADED

=> d 11 .  
L1 HAS NO ANSWERS  
L1 STR



G1 C,N  
G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 15:10:25 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 98 TO ITERATE

100.0% PROCESSED 98 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1367 TO 2553  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 ful  
FULL SEARCH INITIATED 15:10:32 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1945 TO ITERATE

100.0% PROCESSED 1945 ITERATIONS 30 ANSWERS  
SEARCH TIME: 00.00.01

L3 30 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
148.15 148.36

FILE 'CAPLUS' ENTERED AT 15:10:39 ON 25 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Apr 2003. VOL 138 ISS 18  
FILE LAST UPDATED: 24 Apr 2003 (20030424/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13  
L4 9 L3

=> d 14 1- ibib abs hitstr  
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/ (N) :y

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2003:150531 CAPLUS  
DOCUMENT NUMBER: 138:187765  
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi  
PATENT ASSIGNEE(S): G. D. Searle & Company, USA  
SOURCE: U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1998-196623	A2 19981120
			WO 1999-US26007	A1 19991117
			US 1997-47570P	P 19970522
			US 1998-83670	A2 19980522

OTHER SOURCE(S): MARPAT 138:187765  
GI



AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prep'd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.alpha.) and interleukin 1.beta. (IL-1.beta.) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF.alpha..


IT 216504-84-6P 216504-85-7P 216505-37-2P

216505-48-5P 216505-49-6P 216507-06-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
(CA INDEX NAME)




RN 216504-85-7 CAPLUS


CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
(CA INDEX NAME)




RN 216505-37-2 CAPLUS  
CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI)  
(CA INDEX NAME)




RN 216505-48-5 CAPLUS  
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-49-6 CAPLUS  
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-4-pyridinyl- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2003:92403 CAPLUS  
 DOCUMENT NUMBER: 138:137307  
 TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
 INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi  
 PATENT ASSIGNEE(S): G.D. Searle & Company, USA  
 SOURCE: U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144403	A1	20011017	EP 1999-965756	19991117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

BR 9915420	A 20020122	BR 1999-15420	19991117
EE 200100268	A 20021216	EE 2001-20010026819991117	
US 6525059	B1 20030225	US 2000-513351	20000224
NO 2001002456	A 20010719	NO 2001-2456	20010518
US 6423713	B1 20020723	US 2001-918481	20010731
US 1997-47570P P 19970522			
US 1998-83670 A2 19980522			
US 1998-196623 A 19981120			
WO 1999-US26007 W 19991117			

## PRIORITY APPLN. INFO.:

OTHER SOURCE(S) : MARPAT 138:137307  
GI

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prep'd. by soln. phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compd. II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 .mu.M and inhibited tumor necrosis factor .alpha. (TNF.α) and interleukin 1.β release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 .mu.M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF.α.


IT 216504-84-6P 216504-85-7P 216505-37-2P

216505-48-5P 216505-49-6P 216507-06-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; prep'n. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4- [3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
(CA INDEX NAME)




RN 216504-85-7 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
(CA INDEX NAME)




RN 216505-37-2 CAPLUS

CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI)  
(CA INDEX NAME)




RN 216505-48-5 CAPLUS


CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX  
NAME)



RN 216505-49-6 CAPLUS  
 CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-4-pyridinyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:888716 CAPLUS  
 DOCUMENT NUMBER: 137:384853  
 TITLE: Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors of Src and other protein kinases  
 INVENTOR(S): Moon, Young-Choon  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092573	A2	20021121	WO 2002-US15606	20020516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			WO 2002-US15606	20020516
OTHER SOURCE(S):		MARPAT 137:384853		
GI				



I



II

AB Title compds. I [wherein G = XR or XAr; X = independently alkylidene wherein 1-2 non-adjacent methylene units are independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, or NRSO<sub>2</sub>NR; A = N or CR; R = H or (un)substituted aliph. group; or NR<sub>2</sub> = heterocyclyl; Ar = (un)substituted 5-6 membered monocyclic ring with 0-3 heteroatoms or 8-10 membered bicyclic ring with 0-4 heteroatoms; R<sub>1</sub> = TnR or TnAr; n = 0-1; T = CO, CO<sub>2</sub>, COCO, COCH<sub>2</sub>CO, CONR, SO<sub>2</sub>, or SO<sub>2</sub>NR; R<sub>2</sub> = H, Ar, or (un)substituted aliph. group; R<sub>3</sub> = R or Ar; or pharmaceutically acceptable derivs. thereof] were prep'd. as inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli (no data). For example, 3-dimethylamino-1-[5-methyl-3-methylsulfanyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]propanone was coupled with N-(3-benzyloxyphenyl)guanidine in MeOH to give II (40%). I and compns. contg. I are useful in the treatment and prevention of various inflammatory, autoimmune, destructive bone, proliferative, infectious, neurodegenerative, allergic, and cardiac disorders and diseases (no data).

IT 475574-56-2P, N-(3-(Benzylxy)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine  
 475574-57-3P, N-(3-Phenoxyphenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine  
 475574-58-4P, N-(3-Chlorophenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine  
 475574-59-5P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(2-

(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine


**475574-60-8P**, N-(3-(Methoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Src protein kinase inhibitor; prepn. of pyrazolyl pyridinamines and pyrimidinamine inhibitors of protein kinases using condensation, cyclization, and substitution reactions)


RN 475574-56-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-57-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 475574-58-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-59-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475574-60-8 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:591913 CAPLUS

DOCUMENT NUMBER: 137:150215

TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents


INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRIORITY APPLN. INFO.:			JP 2001-18755	20010126
OTHER SOURCE(S):		MARPAT 137:150215		
GI				




AB This invention relates to the general structures (I; Ar = N-contg. hetero arom. ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.

IT 322685-65-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)

RN 322685-65-4 CAPLUS


CN Urea, N-[4-[(1-phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:449675 CAPLUS  
 DOCUMENT NUMBER: 137:33311  
 TITLE: Preparation of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors  
 INVENTOR(S): Leedeboer, Mark; Salituro, Francesco; Moon, Young-Choon  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA  
 SOURCE: PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046184	A1	20020613	WO 2001-US46383	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028783	A5	20020618	AU 2002-28783	20011205
US 2002111353	A1	20020815	US 2001-5133	20011205
PRIORITY APPLN. INFO.:			US 2000-251409P	P 20001205
			WO 2001-US46383	W 20011205

OTHER SOURCE(S): MARPAT 137:33311  
 GI



AB Title compds. (I; R = H or alkyl; R1 = cycloalkyl, Ph, pyridyl, etc.; R2 = H, alkoxyethyl, heterocyclmethyl, etc.; R3 = Ph, CH<sub>2</sub>Ph, etc.; Z1 = pyridine- or pyrimidine-4,2-diyl) were prep'd. Thus, R<sub>4</sub>Z<sub>1</sub>CH(CHO)<sub>2</sub> (R<sub>4</sub> = MeS, Z<sub>1</sub> = pyrimidine-2,4-diyl) was cyclocondensed with H<sub>2</sub>NNHC<sub>6</sub>H<sub>3</sub>F<sub>2</sub>-2,4 and the S-oxidized product aminated by cyclohexylamine to give I (R = R<sub>2</sub> = H, R<sub>1</sub> = cyclohexyl, R<sub>3</sub> = C<sub>6</sub>H<sub>3</sub>F<sub>2</sub>-2,4). Data for biol. activity of I were given.

IT 434283-94-0P 434283-95-1P 434283-96-2P  
 434283-97-3P 434283-98-4P 434283-99-5P  
 434284-00-1P 434284-01-2P 434284-02-3P  
 434284-03-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors)

RN 434283-94-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-


*Applicant's  
pregnant  
pub.*

(9CI) (CA INDEX NAME)




RN 434283-95-1 CAPLUS

CN 2-Pyrimidinamine, 4-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)-N-phenyl- (9CI)  
(CA INDEX NAME)




RN 434283-96-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-phenylamino]-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 434283-97-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[(1-(phenylmethyl)-1H-pyrazol-4-yl)- (9CI)  
(CA INDEX NAME)




RN 434283-98-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-(1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 434283-99-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 434284-00-1 CAPLUS


CN 2-Pyrimidinamine, N-cyclohexyl-4-[1-(2,5-dichlorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 434284-01-2 CAPLUS  
CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 434284-02-3 CAPLUS  
CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)





RN 434284-03-4 CAPLUS  
CN 2-Pyrimidinamine, 4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:78363 CAPLUS  
 DOCUMENT NUMBER: 134:147614  
 TITLE: Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)  
 INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 460 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRIORITY APPLN. INFO.:			JP 1999-211384	A 19990726
			WO 2000-JP4991	W 20000726
OTHER SOURCE(S):	MARPAT 134:147614			
GI				




AB N-(hetero)aryl-N'-heterocyclurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic arom. group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO<sub>2</sub>; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxypyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO<sub>2</sub>, N-(un)substituted NH, SO<sub>2</sub>NH, NHSO<sub>2</sub>NH, NHSO<sub>2</sub>, CONH, NHCO, NHCONH, NHCO<sub>2</sub>, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiophuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepd. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC<sub>50</sub> of 0.061 and 0.019 .mu.M against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 .mu.M, resp., for (.-.-)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC<sub>50</sub> of 0.013 and 0.10 .mu.M, resp., vs. 0.15 and 0.87 .mu.M, resp., for (.-.-)-flavopiridol. Pharmaceutical formulations contg. I were prepd.

IT 322685-65-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of N-(hetero)aryl-N'-heterocyclurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322685-65-4 CAPLUS

CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:368337 CAPLUS

DOCUMENT NUMBER: 133:4656

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi

PATENT ASSIGNEE(S): G.D. Searle & Co., USA

SOURCE: PCT Int. Appl., 1210 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6514977	B1	20030204	US 1998-196623	19981120
EP 1144403	A1	20011017	EP 1999-965756	19991117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO  
 BR 9915420 A 20020122 BR 1999-15420 19991117  
 EE 200100268 A 20021216 EE 2001-20010026819991117  
 US 6525059 B1 20030225 US 2000-513351 20000224  
 NO 2001002456 A 20010719 NO 2001-2456 20010518  
 PRIORITY APPLN. INFO.: US 1998-196623 A 19981120  
 US 1997-47570P P 19970522  
 US 1998-83670 A2 19980522  
 WO 1999-US26007 W 19991117

OTHER SOURCE(S): MARPAT 133:4656

GI




AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepd. by reaction of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product cyclocondensed with TsNHNH<sub>2</sub> to give title compd. II. Data for biol. activity of I were given.

IT 216504-84-6P 216504-85-7P 216505-37-2P

216505-48-5P 216505-49-6P 216507-06-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-84-6 CAPLUS


CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
 (CA INDEX NAME)

RN 216504-85-7 CAPLUS


CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)  
 (CA INDEX NAME)




RN 216505-37-2 CAPLUS  
CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 216505-48-5 CAPLUS  
CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216505-49-6 CAPLUS  
CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 216507-06-1 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-4-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:700930 CAPLUS  
 DOCUMENT NUMBER: 132:151766  
 TITLE: Synthesis and antimicrobial activity of 4-(4-pyrazolyl)-2-aminopyrimidines  
 AUTHOR(S): Singh, Shiv P.; Batra, Hitesh; Naithani, Rajesh; Prakash, Om  
 CORPORATE SOURCE: Department of Chemistry, Kurukshetra University, Kurukshetra, 136 119, India  
 SOURCE: Indian Journal of Heterocyclic Chemistry (1999), 9(1), 73-74  
 CODEN: IJCHEI; ISSN: 0971-1627  
 PUBLISHER: Prof. R. S. Varma  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB 1-(Pyrazol-4-yl)-1,3 butanediones on condensation with guanidine carbonate give 4-(4-pyrazolyl)-2-aminopyrimidines in good yields. A few compds. show moderate level of antimicrobial activity.  
 IT 257625-23-3P 257625-24-4P 257625-25-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and antimicrobial activity of [hydroxy(methyl)pyrazolyl]pyrimid inamines)  
 RN 257625-23-3 CAPLUS  
 CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-phenyl- (9CI) (CA INDEX NAME)




X


2  
 R. not a hydroxyl

10 / 005,133


RN 257625-24-4 CAPLUS  
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1-(4-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 257625-25-5 CAPLUS  
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)




IT 257625-26-6P 257625-27-7P 257625-28-8P  
257625-29-9P 257625-30-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)  
RN 257625-26-6 CAPLUS  
CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1-(2-benzothiazolyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 257625-27-7 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(4-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)




RN 257625-28-8 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 257625-29-9 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-1,3-dimethyl- (9CI)  
(CA INDEX NAME)



RN 257625-30-2 CAPLUS



CN 1H-Pyrazol-5-ol, 4-(2-amino-6-methyl-4-pyrimidinyl)-3-methyl-1-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1998:789144 CAPLUS  
 DOCUMENT NUMBER: 130:38377  
 TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
 INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.; Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard M.; Xu, Xiangdong  
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA; et al.  
 SOURCE: PCT Int. Appl., 828 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852940	A1	19981126	WO 1998-US10436	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9875883	A1	19981211	AU 1998-75883	19980522
AU 754830	B2	20021128		
ZA 9804358	A	19990524	ZA 1998-4358	19980522
EP 1000055	A1	20000517	EP 1998-923642	19980522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900527	A	20000615	EE 1999-527	19980522
BR 9809147	A	20000801	BR 1998-9147	19980522
JP 2002508754	T2	20020319	JP 1998-550650	19980522
NZ 501112	A	20021025	NZ 1998-501112	19980522
NO 9905695	A	20000121	NO 1999-5695	19991119
MX 9910759	A	20000531	MX 1999-10759	19991122
PRIORITY APPLN. INFO.:			US 1997-47570P	P 19970522
			WO 1998-US10436	W 19980522
OTHER SOURCE(S):	MARPAT 130:38377			
GI				



AB Title compds. [I; R1 = H, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepd. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product cyclocondensed with TsNHNH<sub>2</sub> to give title compd. II. Data for biol. activity of I were given.


IT 216504-84-6P 216504-85-7P 216505-37-2P

216505-48-5P 216505-49-6P 216507-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of heteroarylpyrazoles as p38 kinase inhibitors)


RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl] - (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS


CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl] - (9CI) (CA INDEX NAME)



RN 216505-37-2 CAPLUS


10 / 005,133

CN 2-Pyridinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI)  
(CA INDEX NAME)




RN 216505-48-5 CAPLUS

CN 2-Pyrimidinamine, 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 216505-49-6 CAPLUS

CN 2-Pyrimidinamine, N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-4-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:09:55 ON 25 APR 2003)

FILE 'REGISTRY' ENTERED AT 15:10:03 ON 25 APR 2003  
STRUCTURE uploaded

L1 0 S L1  
L2 30 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:10:39 ON 25 APR 2003  
L4 9 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.24	189.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.86	-5.86

STN INTERNATIONAL LOGOFF AT 15:11:30 ON 25 APR 2003